Breast cancer (12.5–41.1%), endometrial cancer (20–34%), colorectal cancer (13–18%) and NSCLC (3.7–19%) have the highest prevalence of PI3K mutations [145,146,147,148,149,150]. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.